A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses

Nuclear Medicine Communications

Volumn 32, Issue 4, 2011, Pages 265-272

  Özülker, Tamer ^a   Özülker, Filiz ^a   Özbek, Emin ^b   Özpaçaci, Tevfik ^a  

^a Okmeydani Training and Research Hospital ^*  (Turkey)

^b OKMEYDANI TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

fluorine 18 fluorodeoxyglucose positron emission tomography; oncology; renal cancer; renal masses; staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; BENIGN TUMOR; CANCER DIAGNOSIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; DRUG EFFICACY; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY CYST; KIDNEY TUMOR; MALE; NEPHRECTOMY; ONCOCYTOMA; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952444019     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283442e3b     Document Type: Review

References (47)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA CancerJ Clin 2007; 57:43-66.
2. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma: age and stage characterization and clinical implications, study of 1092 patients (1982-1997). Urology 2000; 56:58-62. (Pubitemid 30408654)
3. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51:203-205. (Pubitemid 28093168)
4. Ng CS, Wood CG, Silverman PM,Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJRAm J Roentgenol 2008; 191:1220-1232.
5. Kumar R, Chauhan A, Lakhani P, Xiu Y, Zhuang H, Alavi A. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Mol Imaging Biol 2005; 7:431-439. (Pubitemid 44193408)
6. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58:398-406.
7. Hilton S. Imaging of renal cell carcinoma. Semin Oncol 2000; 27:150-159. (Pubitemid 30205370)
8. Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics 2008; 28:1325-1338.
9. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology2004; 231:305-332. (Pubitemid 38552885)
10. Jarritt PH, Carson KJ, Hounsell AR,Visvikis D. The role of PET/CTscanning in radiotherapy planning. Br J Radiol 2006; 79:27-35.
11. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674.
12. Glaspy JA, Hawkins R, Hoh CK, Phelps ME. Use of positron emission tomography in oncology. Oncology 1993; 7:41-50.
13. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495. (Pubitemid 17038084)
14. Monakhov NK, Neistadt EL, Shavlovskil MM, Shvartsman AL, Neifakh SA. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978; 61:27-34. (Pubitemid 8382787)
15. Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18-F)-fluoro-D-glucose: pilot animal and human studies. J Urol1991; 146:1470-1474.
16. Kocher F, Geimmel S, Hauptmann R, Reske SN. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994; 35:223.
17. Bachor R, Kotzerke J, Gottfried HW, Brändle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996; 35:146-150. (Pubitemid 26130554)
18. Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PETcharacterization of renal masses: preliminary experience. Clin Radiol 1997; 52:510-515.
19. Montravers F, Grahek D, Kerrou K, Younsi N, Doublet JD, Gattegno B, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41:78-84. (Pubitemid 30046687)
20. Ramdave S,Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825-830. (Pubitemid 32750957)
21. 18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003; 30:1236-1245. (Pubitemid 37205377)
22. Ak I, Can C. F-18 FDG PET in detecting renal cell carcinoma. Acta Radiol 2005; 46:895-899. (Pubitemid 43102658)
23. Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002; 11:171-178. (Pubitemid 34478435)
24. Volpe A, Panzarella T, Rendon RA. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738-745. (Pubitemid 38176851)
25. Kim JK, Kim TK, Ahn KJ. Differentiation of subtypes of renal cell carcinoma on helical CT scans. Am J Roentgenol 2002; 178:1499-1506. (Pubitemid 34547840)
26. Choyke PL, Amis ES, Bigongiari LR, Bluth EI, Bush WH Jr, Fritzsche P, et al. Renal cell carcinoma staging. American College of Radiology, ACR appropriateness criteria. Radiology 2000; 215:721-725.
27. Reznek RH. CT/MRI in staging renal cell carcinoma. Cancer Imaging 2004; 4 (Spec No A):S25-S32.
28. Nolop KB, Rhodes LG, Boudin LH, Beaney RP, Krausz T, Jones T, et al. Glucose utilization in vivo by human pulmonary neoplasm. Cancer 1987; 60:2682-2689. (Pubitemid 17161799)
29. Kubota K, Matsuzawa T, Fujiwara I, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-1933.
30. Noh DY,Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, et al. Diagnostic value of positron emission tomography for detecting breast cancer. WorldJ Surg 1998; 22:223-227. Discussion 227-228.
31. Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001; 234:675-680. (Pubitemid 33041771)
32. Feldman F,Vanheertum R, Saxena C. 18-fluorodeoxyglucose positron emission tomography evaluation of benign versus malignant osteochondromas: preliminary observations. J ComputAssist Tomogr2006; 30:858-864. (Pubitemid 44368231)
33. Suzuki R, Watanabe H, Yanagawa T, Sato J, Shinozaki T, Suzuki H, et al. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma. Ann Nucl Med 2005; 19:661-670. (Pubitemid 43175526)
34. Kang D, White RL Jr, Zuger J, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. Urol 2004; 171:1806-1809. (Pubitemid 38501007)
35. Miyauchi T, Brown RS, Grossman HB. Correlation between visualization of primary renal cancer by FDG-PETand histopathological findings. Abstract 245. Presented at Forty-third Annual Meeting of the Society of Nuclear Medicine, Denver, Colorado, 3-5 June 1996.
36. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9:15.
37. Seto E, Segall GM, Terris MK. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 2000; 55:286.
38. Wu HC,Yen RF, Shen YY, Kao CH, Lin CC, Lee CC. Comparing whole body 18-F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas: a preliminary report. J Cancer Res Clin Oncol 2002; 128:503.
39. Hain SF, Gleadle J, Maisey MN. F-18 fluorodeoxyglucose PET in the diagnosis of vascular invasion in renal cell carcinoma. Clin Nucl Med 1999; 24:819.
40. Sizemore AW, Jacobs MP, Mantil JC, Hahm GK. FDG uptake in inferior vena cava tumor thrombus from renal cell carcinoma on positron emission tomography. Clin Nucl Med 2007; 32:309-311. (Pubitemid 46569322)
41. 18F-FDG PET. Am J Roentgenol 2006; 186:269-270. (Pubitemid 46100400)
42. Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57:56.
43. Montravers F, Rousseau C, Doublet JD, Gattengo B, Allard S, Fouret P, et al. In-vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma. Nucl Med Commun 1998; 19:953.
44. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44: 540-548. (Pubitemid 39663420)
45. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004; 31:590-595. (Pubitemid 38461575)
46. 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 2005; 26:315-321.
47. Dirisamer A, Halpern BS, Schima W, Heinisch M, Wolf F, Beheshti M, et al. Dual-time point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol 2008; 10:335-340.